Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OncoNano Medicine Inc.

www.onconanomed.com

Latest From OncoNano Medicine Inc.

Finance Watch: Among Multiple Mega-Rounds, Revolution Raises $100m For RAS Programs

Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.

Financing Business Strategies

Venture Funding Deals: Two Companies With China Ties Raise $260m Each

Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OncoNano Medicine Inc.
  • Senior Management
  • Ravi Srinivasan, PhD, Pres. & CEO
    Matthew Head, CFO
    Tian Zhao, PhD, Dir., R&D
  • Contact Info
  • OncoNano Medicine Inc.
    Phone: (408) 476-1904
    5323 Harry Hines Blvd.
    Dallas, TX 75390
    USA
UsernamePublicRestriction

Register